Floatz logo

Crizotinib

ALK-Positive Anaplastic Large Cell Lymphoma

Mingzhi ZhangSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the ALK-Positive Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Mingzhi Zhang
Phase 4BB
Adriamycin
Huiqiang Huang
Phase 2BB
Dexasone
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB
Prednisone
Huiqiang Huang
Phase 2BB

View all 32 →

Same molecule, other indications

Crizotinib is also rated in:

anaplastic large cell lymphomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
inflammatory myofibroblastic tumorActive
BB
Indicative · Phase 4
69 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →